Related by context. All words. (Click for frequent words.) 76 Oral Fingolimod 74 Complicated Skin 74 myelofibrosis polycythemia vera 74 Leukemias 74 Relapsed Refractory 74 Atypical Hemolytic Uremic Syndrome 74 CYT# potent vascular disrupting 74 Myelodysplastic Syndromes 73 complement inhibitor eculizumab 73 Cutaneous T 73 Prolongs Survival 73 Severe Sepsis 73 Myelodysplastic Syndrome 73 Meets Primary Endpoint 73 leukemia AML 73 Overactive Bladder 73 Investigational Treatment 73 Phase 2b Clinical Trial 73 Bronchiectasis 73 essential thrombocythemia ET 73 Advanced Melanoma 73 Chronic Myeloid Leukemia 73 Hepatocellular Carcinoma 73 dasatinib Sprycel ® 73 Follicular Lymphoma 73 Antitumor Activity 73 Epratuzumab 73 Newly Diagnosed Multiple Myeloma 73 Randomized Phase 72 Improves Survival 72 Adjuvant Chemotherapy 72 Chronic lymphocytic leukemia 72 Phase 2b Trial 72 Myelodysplastic Syndrome MDS 72 Refractory Hodgkin Lymphoma 72 Relapsing Multiple Sclerosis 72 Previously Treated 72 Diffuse Large B 72 familial amyloidotic polyneuropathy FAP 72 Hormone Refractory Prostate Cancer 72 Systemic lupus erythematosus SLE 72 Tyrosine Kinase Inhibitor 72 Chronic Myelogenous Leukemia 72 Novel Oral 72 Philadelphia Chromosome Positive 72 erythematosus 72 B Cell Lymphoma 72 Elderly Patients 72 Chronic Lymphocytic Leukemia CLL 72 mycosis fungoides 72 Diabetic Nephropathy 71 Phase IIa Clinical Trial 71 metastatic malignant 71 Progressive Multifocal Leukoencephalopathy 71 idiopathic thrombocytopenic purpura ITP 71 Glioblastoma Multiforme 71 Metastatic Colorectal Cancer 71 Pharmacokinetics PK 71 Anthracycline 71 Node Positive 71 Idiopathic Pulmonary Fibrosis 71 Renal Cell Carcinoma 71 Chronic Lymphocytic Leukemia 71 Lupus Nephritis 71 Brentuximab Vedotin SGN 71 Receives Orphan Drug Designation 71 invasive candidiasis 71 Secondary Hyperparathyroidism 71 Castration Resistant Prostate Cancer 71 Bosutinib 71 Chronic Sinusitis 71 Nilotinib 71 Naive Patients 71 Chronic Hepatitis C 71 Diabetic Foot Ulcer 70 NAGS deficiency 70 Angioedema 70 Pooled Analysis 70 Improves Outcomes 70 Chronic HCV 70 Chronic Bronchitis 70 Initiates Clinical Trial 70 Cell Lymphoma 70 Acute myeloid leukemia 70 Pulmonary Arterial Hypertension 70 Pulmonary Arterial Hypertension PAH 70 Unresectable 70 ara C 70 Relapsing Remitting Multiple Sclerosis 70 Patients Receiving 70 Drug Candidate 70 Malignant Melanoma 70 cell lymphoma CTCL 70 Eculizumab 70 HER2 Positive Breast Cancer 70 Subgroup Analysis 70 Ischemic 70 Metastatic Melanoma 70 Ribavirin causes 70 Tumor Necrosis Factor 70 Romiplostim 70 adalimumab Humira 70 Phase 2a Clinical Trial 70 chronic eosinophilic leukemia 70 Autoimmune Disease 70 Disease Progression 70 Placebo Controlled Study 70 SPRYCEL ® 70 Malignant Glioma 70 Study Evaluating 70 Metastatic Renal Cell Carcinoma 70 Adjuvant Treatment 70 Combination Treatment 70 Gleevec resistant 70 Factor Receptor 70 Radioimmunotherapy 70 PEGylated Fab fragment 70 TNF Blockers 70 Antiviral Therapy 70 atypical Hemolytic Uremic Syndrome 70 hypereosinophilic syndrome 70 Oral Mucositis 70 Progenitor Cells 70 Hormone Receptor Positive 70 Hepatic Encephalopathy 70 Soft Tissue Sarcoma 69 Phase IIb Clinical Trial 69 purpura ITP 69 Peginterferon 69 neutropenia dehydration dyspnea 69 Acute Myelogenous Leukemia 69 Kinase Inhibitor 69 histone deacetylase HDAC inhibitor 69 Generalized Anxiety Disorder 69 pan HDAC inhibitor 69 severe malignant osteopetrosis 69 vWD 69 Fungal Infections 69 Neuroendocrine Tumors 69 Subtypes 69 erlotinib Tarceva ® 69 Acute Ischemic Stroke 69 Plaque Psoriasis 69 Hepatocellular 69 essential thrombocythemia 69 imatinib Gleevec ® 69 HeFH 69 thalidomide Thalomid 69 recurrent glioblastoma multiforme 69 Non Alcoholic Steatohepatitis 69 Prophylactic Treatment 69 Previously Untreated 69 homozygous familial hypercholesterolemia 69 Systemic Lupus Erythematosus SLE 69 cisplatin gemcitabine 69 Epidermal Growth Factor Receptor 69 Thrombocytopenia 69 Lymphocytic 69 Clinical Trial Results 69 Metastatic Prostate Cancer 69 metastatic GIST 69 Patients Treated With 69 Fludarabine 69 Pegylated Liposomal Doxorubicin 69 polycythemia vera essential thrombocythemia 69 kidney urologic 69 Acute Exacerbations 69 sunitinib Sutent ® 69 Completes Enrollment 69 Tezampanel 69 Shows Promising 69 Mouse Model 69 AA Amyloidosis 69 Septic Shock 69 Treatment Naïve 69 Advanced Renal Cell 69 Demonstrates Efficacy 69 Phase IIb Trial 69 atypical hemolytic uremic syndrome 69 Allergic Rhinitis 69 Thrombotic 69 Toxicities 69 LymphoStat B belimumab 69 Safinamide 69 Initiate Phase 69 Diabetic Neuropathy 69 Etanercept 69 IN PATIENTS WITH 69 Anti Tumor 69 systemic anaplastic large 69 Enlarged Prostate 69 Aflibercept 69 Shows Promise Against 69 developing Bicifadine serotonin 69 Glioma 69 Completes Patient Enrollment 69 immune thrombocytopenic purpura 69 Alemtuzumab 69 Drug Shows Promise 69 Files IND 69 Demonstrates Positive 69 myeloid metaplasia 69 Pharmacokinetic Study 69 Endometrial Cancer 69 Acute Myeloid Leukaemia AML 69 Myeloma Patients 69 Newly Diagnosed 69 Voreloxin 68 gastrointestinal stromal tumor GIST 68 Presents Preclinical Data 68 gastrointestinal stromal tumors GIST 68 TO AVOID PREGNANCY WHILE 68 Preclinical Data 68 Cyclophosphamide 68 Natalizumab 68 Novel Treatments 68 Sezary syndrome 68 Myeloid 68 Acute Attacks 68 Paroxysmal Nocturnal Hemoglobinuria PNH 68 Novel Mechanism 68 Hyperkalemia 68 Hsp# Inhibitor 68 Demonstrates Significant 68 Treatment Resistant 68 CYP#A# CYP#D# 68 Bipolar Mania 68 refractory gout 68 alfa 2a 68 chronic myeloid 68 myeloproliferative neoplasms 68 Diabetic Neuropathic Pain 68 pancytopenia 68 myelodysplastic myeloproliferative diseases 68 Trial Evaluating 68 Serious Infections 68 Polycythemia Vera 68 Interferon Beta 68 Shows Efficacy 68 Adjuvant Therapy 68 Vidaza azacitidine 68 dual endothelin receptor antagonist 68 Benign Prostatic Hyperplasia 68 Allogeneic 68 Aurora Kinase 68 Metastases 68 Phospholipase A2 68 Inflammatory Diseases 68 Acute Myelogenous Leukemia AML 68 Decitabine 68 Phase 2a Trial 68 Acute Myeloid Leukemia 68 Azacitidine 68 oral prodrug 68 Chemokine Receptor 68 disease GERD 68 TNF Tumor Necrosis Factor 68 Acute Leukemia 68 Appears Safe 68 Juvenile Idiopathic Arthritis 68 Drug Prevents 68 Chemotherapy Induced 68 Malignancies 68 Slow Progression 68 Long Term Efficacy 68 Localized Prostate Cancer 68 Denufosol 68 PEGylated interferon beta 1a 68 Antifungals 68 Patients Undergoing 68 refractory chronic lymphocytic 68 Renal Cancer 68 Survival Benefit 68 benign prostatic hypertrophy BPH 68 Mg Usa 68 CTAP# Capsules 68 Hypercholesterolemia 68 MKC# MT 68 myeloproliferative diseases 68 Hereditary angioedema HAE 68 GW# [003] 68 Combination REOLYSIN R 68 Successfully Completes Phase 68 T Cell Lymphoma 68 Rheumatoid Arthritis RA 68 imatinib resistant 68 Emerging Therapies 68 gastrointestinal stromal tumor 68 Sipuleucel T 68 Bone Metastases 68 Well Tolerated 68 Rheumatoid Arthritis Patients 68 Peginterferon Alfa 2a 68 Pediatric Patients 68 Investigational Compound 68 Fibrosis 68 Improved Survival 68 Hematological Malignancies 68 Severe Asthma 68 Primary Hypercholesterolemia 68 Vidaza ® 68 JAK Inhibitor 68 Friedreich Ataxia FRDA 68 cytopenias 68 autoimmune disorder characterized 68 pulmonary hypertension PH 68 Chronic Pelvic Pain 68 HDAC Inhibitor 68 ST Elevation Myocardial 68 Improve Survival 68 receptor tyrosine kinase inhibitor 68 Mucositis 68 Initiate Clinical Trial 68 Amgen Neulasta R 68 Randomized Double blind 68 Peginterferon alfa 2b 68 Chronic Hepatitis B 68 Nebulized 68 pheochromocytoma 68 investigational oral inhibitor 68 Growth Hormone Deficiency 68 systemic lupus erythematosus psoriasis 68 candidemia 68 Antiviral Activity 68 steroid refractory ulcerative 68 See CLINICAL PHARMACOLOGY 68 Recombinant Human 67 Skin Structure Infections 67 Clinical Outcome 67 Androgen Receptor 67 hypertrichosis occurred 67 Predict Response 67 Diabetic Macular Edema 67 Carcinoma 67 Slows Progression 67 leukoencephalopathy 67 Enzyme Replacement Therapy 67 Initiates Phase II 67 Preclinical Models 67 Systemic Sclerosis 67 efalizumab 67 Hodgkin lymphoma HL 67 Glufosfamide 67 Non Alcoholic Fatty 67 Neovascular Age Related Macular 67 FUSILEV enhances 67 Host Disease 67 Patients Treated 67 leukemia APL 67 PEGylated anti 67 Acute myeloid leukemia AML 67 induce orthostatic hypotension 67 Irinotecan 67 diarrhea predominant irritable 67 chronic granulomatous disease 67 Lenalidomide 67 cutaneous T 67 Kinase Inhibitors 67 RNAi Therapeutic 67 transthyretin TTR mediated amyloidosis 67 Thromboembolism 67 PNP inhibitor 67 advanced metastatic renal 67 Neoadjuvant Chemotherapy 67 demyelinating disease 67 Dose Ranging Study 67 Anti Tumor Activity 67 R lenalidomide 67 tumors GIST 67 Acute Renal Failure 67 II Clinical Trial 67 cetuximab Erbitux R 67 Resistant Hypertension 67 Dasatinib 67 Advanced Solid Tumors 67 Acute Bacterial Sinusitis ABS 67 dasatinib Sprycel 67 leukemia CLL 67 Squamous 67 Presents Positive 67 HER2 Positive 67 R roscovitine 67 Aliskiren 67 receiving VELCADE 67 cyclophosphamide methotrexate 67 Ankylosing spondylitis 67 Tyrosine Kinase Inhibitors 67 prokinetic agent 67 anterior uveitis 67 Pivotal Phase 67 Omacetaxine 67 Treatment Naive Patients 67 Systemic lupus erythematosus 67 Personalized Immunotherapy 67 systemic autoimmune 67 Colorectal Cancer Patients 67 Phase Ib Clinical Trial 67 JAK2 Inhibitor 67 Gastrointestinal Stromal Tumors 67 Adjunctive Therapy 67 Physician Insights 67 Knee Osteoarthritis 67 non alcoholic steatohepatitis 67 NASH Huntington 67 Chronic Myelogenous Leukemia CML 67 neuroendocrine cancers 67 severe oral mucositis 67 von Willebrand Disease 67 ADPKD 67 psoriatic arthritis PsA 67 FOLOTYN ® 67 Carcinomas 67 metastatic malignant melanoma 67 included exfoliative dermatitis 67 vapreotide acetate 67 Sapacitabine 67 Mitoxantrone 67 Demonstrates Sustained 67 Treating Chronic 67 myocardial infarction ventricular fibrillation 67 Romidepsin 67 Plus Ribavirin 67 Relapsed Refractory Aggressive 67 Lymphomas 67 Platinol ® 67 Enzastaurin 67 Replacement Therapy 67 Pegylated Interferon 67 Polymerase Inhibitor 67 Randomized Phase II 67 SinuNase TM 67 Cell Transplants 67 Gene Linked 67 including thyroiditis RA 67 Estrogen Receptor 67 Immunosuppression 67 Phase III Trial 67 myeloproliferative disorders 67 Glatiramer Acetate 67 Nucleoside 67 Granulocyte Colony Stimulating Factor 67 Mantle Cell Lymphoma 67 Is Well Tolerated 67 metastatic neuroendocrine tumors 67 R Saizen R 67 demonstrated antitumor activity 67 Capecitabine 67 Neoadjuvant 67 Fluorouracil 67 ergot derivatives 67 Chronic Heart Failure 67 Heart Failure Patients 67 Chronic Prostatitis 67 gefitinib Iressa 67 Glucocorticoid 67 Bevacizumab 67 Bipolar Depression 67 Initiates Enrollment 67 Venous thromboembolism 67 hyperplasia BPH 67 Combo Therapy 67 relapsing multiple sclerosis 67 Portal Hypertension 67 Liver Injury 67 gastrointestinal stromal tumors 67 Preclinical Study 67 Treatment Shows Promise 67 Relapsed Refractory Multiple Myeloma 67 Renal Impairment 67 Intravitreal 67 selective modulator 67 Imatinib mesylate 67 Dendritic Cells 66 Treated Patients 66 2 methoxyestradiol 66 dyskeratosis congenita 66 Invasive Breast Cancer 66 Kit CD# positive 66 Orthop Surg 66 Solid Tumors 66 chronic immune thrombocytopenic 66 Idiopathic Thrombocytopenic Purpura ITP 66 Autologous Stem Cell Transplantation 66 Invasive Fungal Infections 66 Lymphoid 66 Lung Cancers 66 Interferon beta 1a 66 Investigational Drug 66 BCG refractory carcinoma 66 Placebo Controlled Trial 66 idiopathic thrombocytopenic purpura 66 Pivotal Phase III 66 pan histone deacetylase 66 overactive bladder syndrome 66 Restenosis 66 Mouse Models 66 immune idiopathic thrombocytopenic 66 transplantation HCT 66 Prognostic Factors 66 Venous Thromboembolism 66 Hyperlipidemia 66 FDA Approvals 66 Microalbuminuria 66 Unstable Angina 66 PKC# 66 EGFR HER2 66 Dementia Related Psychosis 66 Ph + acute lymphoblastic 66 Recurrent Breast Cancer 66 Controlled Trial 66 Gel repository corticotropin injection 66 Cytotoxic 66 Basal Cell 66 relapsing remitting MS RRMS 66 Adenoviral 66 Hedgehog Pathway Inhibitor 66 mastocytosis 66 Orally Active 66 Phase III Pivotal 66 Submits NDA 66 Randomized Study 66 NS5B polymerase 66 Idiopathic Pulmonary Fibrosis IPF 66 Therapeutic Vaccine 66 Intracerebral Hemorrhage 66 leukemia CML 66 Monotherapy 66 Inflammatory Markers 66 targeted radiotherapeutic 66 Renal Anemia 66 Pemphigus Vulgaris 66 5q MDS 66 HoFH 66 orally administered inhibitor 66 INSPIRE Trial Phase III 66 myelodysplastic syndrome MDS 66 relapsed MM 66 Juvenile Idiopathic Arthritis JIA 66 Achieves Primary Endpoint 66 Genetic Variation 66 Fabry Disease 66 AAG geldanamycin analog 66 #-# Full Text 66 J Am Coll 66 Phase 2b Study 66 Antigen Specific 66 Hospital Acquired Pneumonia 66 Patient Enrollment 66 Leber Hereditary Optic Neuropathy 66 Novel Antibiotic 66 Panic Disorder 66 Atopic Dermatitis 66 Stomach Cancer 66 K ras mutations 66 Autoimmune Disorders 66 adriamycin 66 beta 1a 66 Tumor Response 66 Tolvaptan 66 Ambrisentan 66 Graft Versus Host 66 Pemetrexed 66 Pegloticase 66 Autoimmune Diseases 66 Major Depressive Disorder 66 Mg Uk 66 Maribavir 66 Carcinoid tumors 66 MELAS 66 systemic fungal infections 66 Receptor Antagonists 66 Suicidality 66 Treatment Regimen 66 polycythemia vera PV 66 Chronic Insomnia 66 Esophagitis 66 Radiofrequency Ablation RFA 66 Cardiotoxicity 66 FDA Okays 66 relapsed leukemia 66 Pazopanib 66 hematologic disorders 66 Randomized Controlled Trials 66 Metastatic 66 Signaling Pathway 66 acetonide FA 66 Postmenopausal Women 66 Clostridium difficile Infection 66 Prospective Randomized 66 Lowers Risk 66 J Clin 66 Ocrelizumab 66 Known hypersensitivity 66 Gaucher Disease 66 ISTODAX ® 66 Janus kinase 66 Infected Patients 66 Melphalan 66 Chemotherapy induced 66 Bucindolol 66 Critical Limb Ischemia CLI 66 Inflammatory Disease 66 Host Disease GvHD 66 Virus Infection 66 ACE Inhibitors 66 Inhaled Corticosteroids 66 Diabetic Foot Ulcers 66 invasive aspergillosis 66 First Patient Enrolled 66 Prostate Cancer Patients 66 Advanced Prostate Cancer 66 Relapsing 66 Exacerbations 66 Psoriatic arthritis 66 Treatment Reduces 66 non metastatic osteosarcoma 66 Chronic Constipation 66 Cardiovascular Events 66 Pemphigus 66 Mitral Regurgitation 66 5 FU leucovorin 66 acute myeloid 66 IND Application 66 hyperphenylalaninemia HPA due 66 Protease Inhibitor 66 Fondaparinux 66 Erlotinib 66 Hypertensive Patients 66 Vitro Activity 66 Remission Maintenance 66 secondary hyperparathyroidism 66 Dupuytren Contracture 66 ALN HPN 66 Metabolic Disorder 66 Myelodysplastic Syndromes MDS 66 advanced hepatocellular carcinoma 66 investigational monoclonal antibody 66 FDA Accepts 66 Hormone Receptor 66 Papillary 66 temsirolimus Torisel 66 antiangiogenesis therapies 66 Breast Cancer Recurrence 66 Navelbine ® 66 Genes Predict 66 Neutropenia 66 small molecule tyrosine 66 myelofibrosis 66 First Patient Dosed 66 Carbamazepine 66 aplastic anemia AA 66 gemcitabine Gemzar ® 66 Fibrinogen 66 TTR amyloidosis 66 Premenopausal Women 66 novel VDA molecule 66 Squamous Cell Carcinoma 66 J Am Acad 66 Hedgehog Pathway 66 Comorbidities 66 systemic juvenile idiopathic 66 Critical Limb Ischemia 66 Seasonal Allergic Rhinitis 66 Major Depressive Disorder MDD 66 Phase III Clinical Trial 66 Schizoaffective Disorder 66 Immunotherapeutic 66 post transplant lymphoproliferative 66 subependymal giant cell 65 Golimumab 65 MKC# MKC# PP 65 adrenocortical cancer 65 Hypotension 65 Cancer Cachexia 65 superficial basal cell carcinoma 65 Darinaparsin 65 Novel Inhibitor 65 Ischemic Stroke 65 Heterozygous Familial Hypercholesterolemia 65 denileukin diftitox 65 Intracranial Aneurysms 65 Nicotine Vaccine 65 Levels Linked 65 Onychomycosis 65 PAOD 65 Efficacy Results 65 Psoriatic Arthritis 65 carcinoma mCRC 65 antibody MAb 65 Cell Lymphoma CTCL 65 NOMID 65 Aztreonam Lysine 65 Reduces Mortality 65 Albuferon TM 65 Gastric Cancer 65 pemphigus vulgaris 65 Multiple Myeloma MM 65 Bezielle 65 progressive neurodegenerative disorder 65 Abiraterone Acetate 65 SHPT 65 anemia thrombocytopenia 65 thrombocytosis 65 Parnate 65 leukemia ALL 65 Bortezomib 65 Anticancer Activity 65 juvenile myoclonic epilepsy 65 substantially excreted 65 corticotropin injection 65 Initiates Clinical 65 Liver Failure 65 Adalimumab 65 Ventricular Arrhythmias 65 Limb Ischemia 65 pyrexia mucositis sepsis febrile 65 paraganglioma 65 Community Acquired Pneumonia 65 Patients Suffering 65 Idiopathic pulmonary fibrosis 65 diarrhea fatigue asthenia 65 Ceflatonin R 65 Present Preclinical Data 65 Metastatic Pancreatic Cancer 65 Pivotal Trial 65 Psoriasis Drug 65 Oral Formulation 65 panitumumab Vectibix 65 FDA APPROVES 65 selective kinase inhibitor 65 Zollinger Ellison Syndrome 65 hematological diseases 65 non splenectomized 65 sunitinib Sutent 65 Transplant Rejection 65 debilitating autoimmune 65 Receptor Antagonist 65 Pertuzumab 65 Anticancer Drugs 65 cause cardiac channelopathies 65 ST Segment Elevation 65 Pralatrexate 65 paragangliomas 65 oral candidiasis 65 Confirmatory Phase 65 toenail onychomycosis 65 Skin Disorders 65 Hemophilia B 65 precursor acute lymphoblastic 65 Noxafil 65 lichen planus 65 Trabectedin 65 Breast Cancers 65 HP Acthar Gel repository 65 Liver Cancer 65 Adenoma 65 cell lymphoma ALCL 65 Xanafide 65 Interferon Alfa 65 Initiates Dosing 65 Peripheral Artery Disease 65 metastatic gastric 65 Vaccine Adjuvant 65 including cyclosporine methotrexate 65 Fixed Dose 65 Genetic Mutation 65 Begins Dosing 65 Prostate Cancer Vaccine 65 primary Restless Legs 65 Gout Drug 65 Benign prostatic hyperplasia BPH 65 Tiotropium 65 Treat Anemia 65 Daclizumab 65 refractory NSCLC 65 Cholesterol Lowering Drug 65 acute GvHD 65 squamous cell carcinoma SCC 65 pancreatic NET 65 Bazedoxifene 65 esophageal candidiasis 65 paroxysmal nocturnal hemoglobinuria 65 Pulmonary Hypertension 65 colorectal liver metastases 65 Cognitive Impairment 65 arthritis PsA 65 brand ciclesonide HFA 65 triciribine phosphate monohydrate 65 Risk Stratification 65 tumor lysis syndrome 65 stage IIIB 65 rheumatoid arthritis psoriatic arthritis 65 Liprotamase 65 Chronic Renal Failure 65 Vildagliptin 65 Single Dose 65 lupus nephritis 65 Cloretazine 65 interferon beta 1a infertility 65 active ankylosing spondylitis 65 uremic pruritus 65 Carfilzomib 65 CTAP# 65 Systemic Delivery 65 Multiple Sclerosis Rheumatoid Arthritis 65 purpura 65 Acute Myeloid Leukemia AML 65 lupus erythematosus 65 Fingolimod 65 cytomegalovirus infection 65 Xenografts 65 constipation predominant irritable bowel 65 mTOR mammalian target 65 PEGINTRON TM 65 Annamycin 65 heparin induced thrombocytopenia 65 Bosentan 65 dextromethorphan quinidine 65 Immunomodulatory 65 Initiates Phase III 65 Vertebral Fractures 65 Chronic Inflammatory 65 Androgen Deprivation Therapy 65 haematologic 65 Effectively Treats 65 Parathyroid Hormone 65 ATTR PN 65 Proves Effective 65 Medulloblastoma 65 chronic idiopathic thrombocytopenic purpura 65 Psychiatric Disorders 65 efaproxiral 65 psoriasis rheumatoid arthritis 65 Unfractionated Heparin 65 erythematosus SLE 65 Fulvestrant 65 Gefitinib 65 Respiratory Virus 65 Radiofrequency Ablation 65 Vicriviroc 65 Advanced Colorectal Cancer 65 Hematologic 65 Receives Orphan Drug 65 IND Filing 65 Crit Rev 65 Candidiasis 65 Lupus Drug 65 basal cell carcinoma BCC 65 antiphospholipid syndrome 65 Novel Compound 65 Ranolazine 65 Chemoradiation 65 First Patient Treated 65 Postmenopausal Osteoporosis 65 topical gel formulation 65 Ozarelix 65 Dose Escalation 65 cell carcinoma RCC 65 J Am Soc 65 Ibritumomab Tiuxetan 65 chronic thromboembolic pulmonary 65 Acute lymphoblastic leukemia 65 Increased Mortality 65 Vitrasert R 65 Adefovir 65 C1 INH deficiency 65 Successfully Treated 65 Pafuramidine 65 Presents Preclinical 65 Kidney Transplant Patients 65 paclitaxel Taxol 65 Pancreatic Adenocarcinoma 65 Meta Analysis 65 Trastuzumab 65 systemic mastocytosis 65 Boceprevir 65 Meningiomas 65 Pegylated 65 Waldenstrom macroglobulinemia 65 Granted Orphan Drug 65 primary immunodeficiency PI 65 Chemotherapeutic Agents 65 Vidofludimus 65 Tanespimycin 65 Mycophenolate Mofetil 65 Potent Antiviral Activity 65 Phase III Trials 65 Iron Overload 65 Monoclonal 65 Gets FDA Clearance 65 Tumor Targeting 65 idiopathic myelofibrosis 65 novel emulsion formulation 65 Diagnostic Criteria 65 Fludara ® 65 Interferon beta 65 itraconazole Sporanox 65 BiovaxID TM 65 B Cell Malignancies 65 chronic myelogenous leukemia CML 65 AAT Deficiency 65 demethylation agents 65 Inhibits 65 Telaprevir VX 65 eosinophilic asthma 65 occlusion PAO 65 Demonstrated Significant 65 Erythropoietic 65 Rheumatoid 65 Thromboembolic 65 immunomodulatory therapy 65 neuropathic pain metabolic diseases 65 Kidney Failure 65 Gene Mutation 65 Drug Resistant 65 Study Shows Promise 65 secondary hyperparathyroidism SHPT 65 Hepatitis C Genotype 65 NDA Submission 65 Multiple Myeloma Patients 65 Camptosar ® irinotecan 65 Recurrent Glioblastoma 65 Demonstrates Potential 65 Heart Transplant Recipients 65 neurological manifestations 65 sorafenib Nexavar 65 pediatric Crohn disease 65 myoclonus 65 Diabetic nephropathy 65 Blinatumomab 65 INCB# [003] 65 Pivotal Study 65 JAK2 enzyme 65 Gleevec imatinib mesylate 65 AVONEX ® 65 MGd 65 Liver Tumors 65 Parkinson Disease PD 65 ACTEMRA TM 65 Adjunctive 65 Monoclonal Antibody 65 alkylating agent 65 ANN INTERN MED 65 Hepatotoxicity 65 interferon gamma 1b 65 CYP#A# substrate 65 leiomyomas 65 Antiangiogenic 65 J Shoulder Elbow 65 Mimetics 64 Asthma COPD 64 Gliomas 64 Candida infection 64 Sustained Reduction 64 MAGE A3 ASCI 64 Vandetanib 64 Cell Proliferation 64 Inflammatory Arthritis 64 Combination Therapy 64 aripiprazole Abilify 64 Infusion Reactions Severe 64 polyneuropathy HIV DSP 64 Ulcerative Colitis 64 recurrent sinusitis 64 HCV Protease Inhibitor 64 LHRH receptor positive 64 pralatrexate injection folate analogue 64 Critically Ill Patients 64 Teva Provides Update 64 epithelial tumors 64 Lung Cancer Drug 64 tumor xenograft models 64 resistant hormone refractory 64 Systemic Lupus Erythematosus 64 Treatable 64 gastric adenocarcinoma 64 Breast Cancer Treatment 64 Stem Cell Transplants 64 immunomodulatory agents 64 Statistically Significant 64 Amrubicin 64 Minimally Invasive Treatment 64 Mylan Receives Approval 64 Adult Stem Cell Therapy 64 Silodosin 64 recurrent glioblastoma 64 Attenuates 64 novel topoisomerase 64 Exacerbation 64 Female Sexual Arousal 64 chronic constipation CC 64 MyVax R 64 Comorbid 64 Temsirolimus 64 FOLFOX6 64 Dilated Cardiomyopathy 64 peripheral neuropathy aggravated 64 Phase 1b Clinical Trial 64 ORLive Presents